JP2017511365A5 - - Google Patents

Download PDF

Info

Publication number
JP2017511365A5
JP2017511365A5 JP2016562835A JP2016562835A JP2017511365A5 JP 2017511365 A5 JP2017511365 A5 JP 2017511365A5 JP 2016562835 A JP2016562835 A JP 2016562835A JP 2016562835 A JP2016562835 A JP 2016562835A JP 2017511365 A5 JP2017511365 A5 JP 2017511365A5
Authority
JP
Japan
Prior art keywords
triazolo
optionally substituted
amino
pyrazin
pyrazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016562835A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017511365A (ja
Filing date
Publication date
Priority claimed from PCT/CN2014/075560 external-priority patent/WO2015157955A1/en
Application filed filed Critical
Publication of JP2017511365A publication Critical patent/JP2017511365A/ja
Publication of JP2017511365A5 publication Critical patent/JP2017511365A5/ja
Pending legal-status Critical Current

Links

JP2016562835A 2014-04-17 2015-04-16 複素環キナーゼ阻害薬 Pending JP2017511365A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2014/075560 2014-04-17
PCT/CN2014/075560 WO2015157955A1 (en) 2014-04-17 2014-04-17 Heterocyclic btk inhibit ors
PCT/CN2015/076766 WO2015158283A1 (en) 2014-04-17 2015-04-16 Heterocyclic kinase inhibitors

Publications (2)

Publication Number Publication Date
JP2017511365A JP2017511365A (ja) 2017-04-20
JP2017511365A5 true JP2017511365A5 (enExample) 2018-05-31

Family

ID=54323386

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016562835A Pending JP2017511365A (ja) 2014-04-17 2015-04-16 複素環キナーゼ阻害薬

Country Status (9)

Country Link
US (2) US10280184B2 (enExample)
EP (1) EP3131900A4 (enExample)
JP (1) JP2017511365A (enExample)
CN (1) CN106459045A (enExample)
AU (1) AU2015246482A1 (enExample)
BR (1) BR112016024057A2 (enExample)
CA (1) CA2946036A1 (enExample)
MX (1) MX2016013564A (enExample)
WO (2) WO2015157955A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9932340B2 (en) * 2014-12-18 2018-04-03 Abbvie Inc. Substituted indoles
MX2017014436A (es) * 2015-05-12 2018-08-01 Kalyra Pharmaceuticals Inc Compuestos biciclicos.
KR20180094906A (ko) * 2015-11-20 2018-08-24 밍사이트 파마슈티칼스, 인크. 자가면역 질환의 치료
WO2017163078A1 (en) * 2016-03-24 2017-09-28 Mission Therapeutics Limited 1-cyano-pyrrolidine derivatives as dbu inhibitors
GB201616511D0 (en) * 2016-09-29 2016-11-16 Mission Therapeutics Limited Novel compounds
WO2018098491A1 (en) 2016-11-28 2018-05-31 Praxis Precision Medicines, Inc. Compounds and their methods of use
EP4397308A3 (en) 2016-11-28 2024-08-21 Praxis Precision Medicines, Inc. Compounds and their methods ofuse
US11492345B2 (en) 2017-02-13 2022-11-08 Praxis Precision Medicines, Inc. Compounds and their methods of use
IL269152B2 (en) 2017-03-22 2023-11-01 Liao Xibin Bruton's tyrosine kinase inhibitors
US11731966B2 (en) 2017-04-04 2023-08-22 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11278535B2 (en) 2017-08-15 2022-03-22 Praxis Precision Medicines, Inc. Compounds and their methods of use
PE20211001A1 (es) 2018-02-27 2021-06-01 Incyte Corp Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b
MA52940A (fr) 2018-05-18 2021-04-28 Incyte Corp Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b
TWI831786B (zh) 2018-05-30 2024-02-11 美商普雷西斯精密藥品公司 離子通道調節劑
GEP20237560B (en) * 2018-07-05 2023-10-25 Incyte Corp Fused pyrazine derivatives as a2a / a2b inhibitors
EA202092908A1 (ru) 2018-09-28 2021-05-14 Праксис Пресижн Медсинз, Инк. Модуляторы ионных каналов
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
US11773099B2 (en) 2019-05-28 2023-10-03 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11505554B2 (en) 2019-05-31 2022-11-22 Praxis Precision Medicines, Inc. Substituted pyridines as ion channel modulators
US11279700B2 (en) 2019-05-31 2022-03-22 Praxis Precision Medicines, Inc. Ion channel modulators
CN114555595B (zh) * 2019-08-30 2023-12-26 Tsd生命科学有限公司 咪唑并吡啶衍生物及将其作为有效成分的药学组合物
US11767325B2 (en) 2019-11-26 2023-09-26 Praxis Precision Medicines, Inc. Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators
EP3915990A1 (en) 2020-05-26 2021-12-01 Centre National de la Recherche Scientifique 4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-3,6-dihydropyridine-1-(2h)-carboxamide derivatives as limk and/or rock kinases inhibitors for use in the treatment of cancer
CN115916782B (zh) * 2020-06-01 2024-08-13 南京瑞捷医药科技有限公司 化合物及其作为脾酪氨酸激酶抑制剂的应用
WO2021249417A1 (zh) * 2020-06-09 2021-12-16 赛诺哈勃药业(成都)有限公司 杂环化合物及其衍生物
GB202014114D0 (en) * 2020-09-08 2020-10-21 Synairgen Res Ltd Use of inhaled interferon-beta to treat virus-induced exacerbations in copd patients undergoing treatment with a systemic corticosteroid
CN116783199A (zh) * 2020-11-13 2023-09-19 渤健马萨诸塞州股份有限公司 作为btk抑制剂的吡唑并[1,5-a]吡嗪衍生物
US20250304586A1 (en) * 2022-05-10 2025-10-02 Biogen Ma Inc. Crystalline polymorphs of n-methyl-n-((1s,3s)-3-methyl-3-((6-(1-methyl-1h-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)cyclobutyl)acrylamide

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002060492A1 (en) * 2001-01-30 2002-08-08 Cytopia Pty Ltd Methods of inhibiting kinases
SK10272003A3 (sk) * 2001-03-09 2004-07-07 Pfizer Products Inc. Triazolopyrimidýny ako protizápalové činidlá
WO2005014599A1 (en) * 2003-06-04 2005-02-17 Cellular Genomics, Inc. Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds
WO2005085252A1 (en) * 2004-03-04 2005-09-15 Biofocus Discovery Limited Imidazo ‘1,2-a’ pyrazine compounds which interact with protein kinases
DE102004030782A1 (de) * 2004-06-25 2006-01-19 Fev Motorentechnik Gmbh Fahrzeug-Steuergerät mit einem neuronalen Netz
EP1812439B2 (en) 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinase inhibitors
CN101300233A (zh) * 2005-09-09 2008-11-05 先灵公司 氮杂稠合的细胞周期蛋白依赖性激酶抑制剂
DE102007032349A1 (de) * 2007-07-11 2009-01-15 Bayer Healthcare Ag Imidazo-, Pyrazolopyrazine und Imidazotriazine und ihre Verwendung
PE20091074A1 (es) * 2007-12-13 2009-07-26 Bayer Healthcare Ag Triazolotriazinas y triazolopirazinas y su uso
ES2462642T3 (es) 2007-12-14 2014-05-26 F. Hoffmann-La Roche Ag Nuevos derivados de imidazo[1,2-a]piridina e imidazo[1,2-b]piridazina
JP5318952B2 (ja) 2008-07-15 2013-10-16 エフ.ホフマン−ラ ロシュ アーゲー 新規なフェニル−イミダゾピリジン類及びピリダジン類
TWI453207B (zh) * 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶,其組合物及使用其之治療方法
CA2745871C (en) 2008-12-08 2018-02-20 Gilead Connecticut, Inc. Imidazopyrazine syk inhibitors
WO2010068806A1 (en) * 2008-12-10 2010-06-17 Cgi Pharmaceuticals, Inc. Amide derivatives as btk inhibitors in the treatment of allergic, autoimmune and inflammatory disorders as well as cancer
WO2010068810A2 (en) * 2008-12-10 2010-06-17 Cgi Pharmaceuticals, Inc. Certain substituted amides, method of making, and method of use thereof
EP2343294A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
EP2545052B1 (en) 2010-03-11 2014-11-12 Gilead Connecticut, Inc. Imidazopyridines syk inhibitors
TWI541243B (zh) 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
US20140187548A1 (en) 2010-12-17 2014-07-03 Bayer Intellectual Property Gmbh 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
WO2012136531A1 (en) 2011-04-06 2012-10-11 Bayer Pharma Aktiengesellschaft Substituted imidazopyridines and intermediates thereof
WO2012163724A1 (en) * 2011-05-31 2012-12-06 F. Hoffmann-La Roche Ag Triazolopyridine compounds
EP2773645A1 (en) * 2011-11-01 2014-09-10 F.Hoffmann-La Roche Ag Imidazopyridazine compounds
JP5808869B2 (ja) 2011-11-03 2015-11-10 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 二環式ピペラジン化合物
HK1200816A1 (en) 2011-12-09 2015-08-14 F. Hoffmann-La Roche Ag Inhibitors of bruton's tyrosine kinase

Similar Documents

Publication Publication Date Title
JP2017511365A5 (enExample)
JP7323723B2 (ja) Nav1.8阻害剤としての2-オキソイミダゾリジン-4-カルボキサミド
JP7398391B2 (ja) N-[4-オキソ-2,3-ジヒドロ-1,5-ベンズオキサゼピン-3-イル]-5,6-ジヒドロ-4H-ピロロ[1,2-b]ピラゾール-2-カルボキサミド誘導体及び例えば過敏性腸症候群(IBS)を処置するためのRIP1キナーゼ阻害剤としての関連化合物
US9617258B2 (en) Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides
HRP20201641T1 (hr) Novi spojevi i njihove farmaceutske kompozicije za liječenje inflamatornih poremećaja
RU2019115115A (ru) Производные пиперидина в качестве ингибиторов убиквитин-специфической протеазы 7
JP2016523911A5 (enExample)
WO2011157397A1 (en) Heteroaryl imidazolone derivatives as jak inhibitors
RU2009136299A (ru) Новые производные 3-({1,2,4}триазоло{4,3-а}пиридин-7-ил)бензамида
TW201725202A (zh) 新穎經取代吲唑、其製法、包含其之醫藥製劑及其製備藥劑之用途
US9040534B2 (en) [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators
JP2013539762A (ja) フロ[3,2−d]ピリミジン化合物
JP2020526549A5 (enExample)
JP2017193592A5 (enExample)
SI3083625T1 (en) Pyrimidopyrimidinones, useful as Wee-1 kinase inhibitors
JP2017511365A (ja) 複素環キナーゼ阻害薬
JP2013533868A (ja) タンパク質チロシンキナーゼ阻害剤としての新規ホモピペラジン誘導体およびそれらの医薬使用
JP2017531672A5 (enExample)
JP2020536915A5 (enExample)
JP2017501177A5 (enExample)
JPWO2021113479A5 (enExample)
JPWO2021224636A5 (enExample)
JPWO2020207991A5 (enExample)
JPWO2023064366A5 (enExample)
JPWO2023067355A5 (enExample)